CT

Cytovia Therapeutics

Request removal

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. We are developing three types of iPSC-derived Natural Killer cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multispecific antibody platform designed to engage natural killer cells by targeting NKp46 using a proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Clinical studies are expected to initiate in 2022. Cytovia's R&D laboratories in Natick, MA and GMP cell manufacturing facility in Puerto Rico are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia Therapeutics has recently formed CytoLynx Therapeutics, a joint-venture entity focused on research and development, manufacturing, and commercialization activities in Greater China and beyond. Find out more at www.cytoviatx.com.

Get valid emails for people working at Cytovia Therapeutics and 200M other companies
20 free emails each month. No credit card required.
500M
Business Profiles
20M
Company Profiles
200M
Email addresses
98%+
Email Delivery
Cytovia Therapeutics's headquarter address
Cytovia Therapeutics's industries
Biotechnology Research
Cytovia Therapeutics's technology
DoubleClick Facebook Login (Connect) Google Cloud Hosting Google Tag Manager MailChimp SPF Mobile Friendly Outlook Shutterstock Varnish Wix YouTube
People working at Cytovia Therapeutics
AP
An-Ping Chen, Ph.D
Associate Director
Miami, Florida, United States
GM
Gregory Fiore MD
Member Board of Directors
Miami, Florida, United States
DZ
David Z.
Director of Cell Therapy
Miami, Florida, United States
'M
'Marshall' Chao Ma
DT
Daniel Teper
Co-Founder,Chairman & CEO
MG
Michael Gershenovich
Scientist
Miami, Florida, United States
DP
David Calligaris, PhD, PMP
Project Manager - Cell Therapy
Miami, Florida, United States
HP
Harish Potu
Senior Scientist-Preclinical Research (CAR-NK)
Miami, Florida, United States
WP
Wei Li, Ph.D
Chief Scientific Officer
Miami, Florida, United States
PG
Peng Gao
Research Scientist
Miami, Florida, United States
You can find 38 people working at Cytovia Therapeutics on FinalScout. Create a free account to view details including email addresses.
Scrape emails from LinkedIn for free
20 free emails each month. No credit card required.
Regular search results
Search for leads on linkedin.com and scrape the search results
Sales Navigator search results
Search for leads in LinkedIn sales navigator and scrape the search results
Group members
Scrape members from any LinkedIn group without joining it
Event attendees
Scrape event attendees from any LinkedIn event
Directory